PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 20, 2024Clinical Nuclear Medicine3 citations

177Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors

View Full Paper
MMMagdalena MilevaCBCamille Van BogaertGMGwennaëlle Marin

Key Points

Key points are not available for this paper at this time.

Abstract

The aim of this study was to assess the association among toxicity, dosimetry of organs-at-risk, and disease progression in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with 177 Lu-DOTATATE.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mileva et al. (2024) studied this question.

synapsesocial.com/papers/68e63f56b6db6435875d088ehttps://doi.org/10.1097/rlu.0000000000005330
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Bone Marrow Absorbed Doses and Correlations with Hematologic Response During 177 Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases2019 · 90 citations
  2. 2Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning2018 · 148 citations
  3. 3The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes2009 · 4,440 citations
  4. 4Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade2021 · 240 citations
  5. 5A pilot study of pembrolizumab and peptide receptor radionuclide therapy for patients with metastatic well-differentiated neuroendocrine tumors2023 · 1 citations